Bioxcel Therapeutics Stock Investor Sentiment
| BTAI Stock | USD 0.41 0.04 8.89% |
Under 67% of BioXcel Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding BioXcel Therapeutics suggests that many traders are alarmed. BioXcel Therapeutics' investing sentiment shows overall attitude of investors towards BioXcel Therapeutics.
BioXcel |
BioXcel Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards BioXcel Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about BioXcel Therapeutics that are available to investors today. That information is available publicly through BioXcel media outlets and privately through word of mouth or via BioXcel internal channels. However, regardless of the origin, that massive amount of BioXcel data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of BioXcel Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of BioXcel Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to BioXcel Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive BioXcel Therapeutics alpha.
BioXcel Therapeutics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Disposition of 521 shares by Frank Yocca of BioXcel Therapeutics subject to Rule 16b-3 | 09/06/2024 |
2 | Acquisition by Matthew Wiley of 750 shares of BioXcel Therapeutics subject to Rule 16b-3 | 09/13/2024 |
3 | Disposition of 215 shares by Matthew Wiley of BioXcel Therapeutics at 0.6908 subject to Rule 16b-3 | 09/16/2024 |
4 | Mizuho maintains Neutral rating on BioXcel Therapeutics stock - Investing.com | 09/23/2024 |
5 | Disposition of 2610 shares by Vimal Mehta of BioXcel Therapeutics subject to Rule 16b-3 | 09/26/2024 |
6 | Disposition of 5556 shares by Oneill Vincent of BioXcel Therapeutics at 0.55 subject to Rule 16b-3 | 10/03/2024 |
7 | BioXcel Therapeutics CSO sells shares worth 3,946 | 10/04/2024 |
8 | BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 for Treating Acute Stress Disorder | 10/15/2024 |
9 | BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024 | 11/08/2024 |
10 | BioXcel Therapeutics Inc Reports Q3 2024 Earnings Net Revenue at 214K, Net Loss Narrows to 13.7M | 11/14/2024 |
11 | BioXcel Therapeutics Inc Q3 2024 Earnings Call Highlights Strategic Trials and ... | 11/15/2024 |
12 | BioXcel Therapeutics amends credit agreement, issues new warrants | 11/21/2024 |
13 | BioXcel Therapeutics Announces Pricing of 7.0 Million Public Offering | 11/22/2024 |
Complementary Tools for BioXcel Stock analysis
When running BioXcel Therapeutics' price analysis, check to measure BioXcel Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioXcel Therapeutics is operating at the current time. Most of BioXcel Therapeutics' value examination focuses on studying past and present price action to predict the probability of BioXcel Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioXcel Therapeutics' price. Additionally, you may evaluate how the addition of BioXcel Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |